Antibody cuts migraine frequency in difficult-to-treat cases
A large international study shows fremanezumab is an effective prevention therapy
The human monoclonal antibody, fremanezumab, can rapidly halve migraine frequency in some difficult-to-treat patients, an international trial shows.
The 838 patients randomised to two fremanezumab arms and a placebo arm in the trial were aged 18-70 and had difficult-to-treat disease, which had failed to improve with 2-4 classes of migraine preventive therapies.
